Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about treatment/resistant depression

Recent news which mentions treatment/resistant depression

Atai's DMT Depression Drug Shows Promise, Prepares For Phase II Trial And Future Collaboration With Pharma Giant
Tickers ATAI
Tags Cannabis Market News Florian Brand
From Benzinga
Pharma Giant Johnson & Johnson Asks FDA To Approve Esketamine Nasal Spray For Treatment-Resistant Depression
Tickers JNJ NEWS
Tags JNJ eketamine nasal spray premium
From Benzinga
First Patient Dosed In Psychedelics Therapy Study For Treatment-Resistant Depression
Tickers NEWS
Tags treatment/resistant depression 5/MeO/DMT Beckley Psytech
From Benzinga
Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression
Tickers ATAI NEWS
Tags News ATAI treatment/resistant depression
From Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
Tickers CMPS
Tags Market News Cannabis treatment/resistant depression
From Benzinga
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
Tickers AWKNF CMPS
Tags Ketamine/Assisted Therapy MHRA AWKNF
From Benzinga
Atai Life Sciences Completes Phase 1 Clinical Study Of Oral Film DMT Formulation
Tickers ATAI
Tags Management Psychedelic/Assisted Therapies Psychedelics
From Benzinga
Compass Pathways Explores AI-Powered Predictive Model On Psilocybin Therapy For Depression
Tickers CMPS
Tags Management CMPS Small Cap
From Benzinga
GH Research Psychedelics Firm Q2 2023 Reports $238M Cash To Accelerate 5-MeO-DMT Programs Into 2026
Tickers GHRS
Tags Markets Market News Cannabis
From Benzinga
Compatibility Of Psilocybin & SSRIs For Depression, COMPASS Looks At 'Psychedelic-Assisted Therapies'
Tickers CMPS
Tags News Cannabis Market News
From Benzinga
COMPASS Pathways Secures Up To $50M In Term Loan Facility With Hercules Capital
Tickers ATAI CMPS HTGC
Tags Market News Cannabis Markets
From Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
Tickers CMPS NUMIF
Tags Psychedelics Benzinga Psilocybin program
From Benzinga
GH Research: Q1 2023 Financials And Businesses For European 5-MeO-DMT Depression Treatment Developer
Tickers GHRS
Tags treatment/resistant depression Cannabis Market News
From Benzinga
Beckley Psytech Begins Phase IIa Study Of Psychedelic Compound To Treat Depression
Tags News Cannabis Market News
From Benzinga
Cathie Wood Reacts To Atai's Drastic Stock Plunge After Doomed Clinical Study Results
Tickers ATAI CMPS IGXT
Tags atai Small Cap CMPS
From Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
Tickers CMPS
Tags psilocybin therapy CMPS Small Cap
From Benzinga
Psychedelics And Treatment-Resistant Depression: COMPASS Pathways Replies To Comments
Tickers CMPS
Tags Dr/ Steve Levine Benzinga Psychedelics
From Benzinga
Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes
Tickers CMPS
Tags Psychedelics Benzinga CMPS
From Benzinga
Psychedelics Company's $60M Series A For Startup To Develop Treatment For Mental Health Disorders
Tags Markets Catalent Market News
From Benzinga
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Tickers ATAI
Tags ATAI Life Sciences News DMT Clinical Trial
From Benzinga
Psilocybin For Anorexia: Learn About Compass' Novel Phase 2 Trial Using Magic Mushroom's Main Compound
Tickers CMPS
Tags COMP360 COMPASS Pathways PLC News
From Benzinga
Psilocybin More Effective Than Antidepressants In Treating Depression, New Study Shows
Tags Market News Cannabis Markets
From Benzinga
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
Tickers CMPS
Tags treatment/resistant depression Market News Cannabis
From Benzinga
Mike Tyson: How A Drug Derived From Toad Venom Made Him Comfortable With Dying
Tickers GHRS
Tags Health Care Success Stories GHRS
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.